EcoDrugPlus

Potassium Voltage-Gated Channel Subfamily A Member 5

Ensembl ID : ENSSVLG00005011478
Gene Symbol: KCNA5
1 Cross references
169 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily D Member 3

Ensembl ID : ENSSVLG00005018411
Gene Symbol: KCND3
1 Cross references
259 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily H Member 2

Ensembl ID : ENSSVLG00005009247
Gene Symbol: KCNH2
1 Cross references
252 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 2

Ensembl ID : ENSSVLG00005004604
Gene Symbol: KCNQ2
1 Cross references
248 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 3

Ensembl ID : ENSSVLG00005015209
Gene Symbol: KCNQ3
1 Cross references
191 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 5

Ensembl ID : ENSSVLG00005009032
Gene Symbol: KCNQ5
1 Cross references
278 Possible Orthologues:

Presenilin 1

Ensembl ID : ENSSVLG00005007728
Gene Symbol: PSEN1
1 Cross references
200 Possible Orthologues:

Presenilin 2

Ensembl ID : ENSSVLG00005010078
Gene Symbol: PSEN2
1 Cross references
205 Possible Orthologues:

Presenilin Enhancer, Gamma-Secretase Subunit

Ensembl ID : ENSSVLG00005010696
Gene Symbol: PSENEN
1 Cross references
183 Possible Orthologues:

Progesterone Receptor

Ensembl ID : ENSSVLG00005012195
Gene Symbol: PGR
1 Cross references
193 Possible Orthologues:

Prostaglandin D2 Receptor

Ensembl ID : ENSSVLG00005007172
Gene Symbol: PTGDR
1 Cross references
118 Possible Orthologues:

Prostaglandin D2 Receptor 2

Ensembl ID : ENSSVLG00005010766
Gene Symbol: PTGDR2
1 Cross references
206 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).